RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today a collaboration with the European Group for the Study of Insulin Resistance (EGIR). The EGIR has compiled large numbers of biological samples from studies conducted at 19 clinical research centers across Europe as part of their effort to understand insulin resistance and how it affects disease. Metabolon will discover and validate the biomarkers found in these samples that relate to insulin resistance. These markers will be used to help further develop Metabolon’s diagnostic test for pre-diabetic patients.
